Provided by Tiger Trade Technology Pte. Ltd.

Kazia Therapeutics Limited

13.41
-0.2650-1.94%
Post-market: 13.410.00000.00%19:30 EDT
Volume:148.99K
Turnover:1.99M
Market Cap:153.18M
PE:-1.97
High:13.96
Open:13.67
Low:13.06
Close:13.67
52wk High:17.40
52wk Low:4.86
Shares:11.43M
Float Shares:8.68M
Volume Ratio:1.13
T/O Rate:1.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.8190
EPS(LYR):-12.3849
ROE:-106.90%
ROA:-25.70%
PB:4.60
PE(LYR):-1.08

Loading ...

Kazia Therapeutics in-licenses SETDB1 platform from QIMR Berghofer for $1.39 million upfront

Reuters
·
Apr 14

Kazia Therapeutics files Form 3 as David Cain named Director, CMC

Reuters
·
Apr 01

Kazia Therapeutics Ltd: on March 26, 2026, Bryce Carmine, the Current Chairman of the Board, Notified the Board of His Intent to Retire

THOMSON REUTERS
·
Apr 01

Kazia Therapeutics Director Steven R. S. Coffey Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

Kazia Therapeutics files initial beneficial ownership statement for CEO John E. Friend II

Reuters
·
Mar 19

Kazia Therapeutics’ Program Director Jeremy Simpson files initial beneficial ownership statement

Reuters
·
Mar 19

Kazia Therapeutics Limited VP of Finance and Controller Jeffrey Bonacorda files Form 3 initial beneficial ownership statement

Reuters
·
Mar 19

Kazia Therapeutics files Form 3 initial beneficial ownership statement for Director Robert F Apple

Reuters
·
Mar 19

BRIEF-Kazia Therapeutics Ltd Files For Offering Of Up To $200 Million Of American Depositary Shares Representing Ordinary Shares Or Warrants - SEC Filing

Reuters
·
Mar 18

Kazia Therapeutics Ltd Files for Offering of up to $200 Mln of American Depositary Shares Representing Ordinary Shares or Warrants - SEC Filing

THOMSON REUTERS
·
Mar 18

Kazia Therapeutics H1 net loss widens 20.08% to AUD 12.55 million

Reuters
·
Mar 16

Kazia Therapeutics Limited Releases 2025 Annual Report

Reuters
·
Feb 11

Kazia Therapeutics Ltd - Plans First-in-Human Clinical Trials for Ndl2 in 2027

THOMSON REUTERS
·
Jan 30

Kazia Therapeutics Ltd - Ndl2 Shows Reversal of Immune Exhaustion and Enhanced Anti-Tumor Activity

THOMSON REUTERS
·
Jan 30

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear Pd-L1 Degrader (Ndl2)

THOMSON REUTERS
·
Jan 30

Kazia Therapeutics Unveils Promising Preclinical Data for Nuclear PD-L1 Degrader

Reuters
·
Jan 30